Cited by 534Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchMemory and Neural Mechanisms

Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling

Open access
Vitolo, Ottavio V., Sant'Angelo, Antonino, Costanzo, Vincenzo, Battaglia, Fortunato, Arancio, Ottavio, Shelanski, Michael·2002·Proceedings of the National Academy of Sciences

Abstract

Changes in hippocampal function seem critical for cognitive impairment in Alzheimer's disease (AD). Although there is eventual loss of synapses in both AD and animal models of AD, deficits in spatial memory and inhibition of long-term potentiation (LTP) precede morphological alterations in the models, suggesting earlier biochemical changes in the disease. In the studies reported here we demonstrate that amyloid beta-peptide (Abeta) treatment of cultured hippocampal neurons leads to the inactivation of protein kinase A (PKA) and persistence of its regulatory subunit PKAIIalpha. Consistent with this, CREB phosphorylation in response to glutamate is decreased, and the decrease is reversed by rolipram, a phosphodiesterase inhibitor that raises cAMP and leads to the dissociation of the PKA catalytic and regulatory subunits. It is likely that a similar mechanism underlies Alphabeta inhibition of LTP, because rolipram and forskolin, agents that enhance the cAMP-signaling pathway, can reverse this inhibition. This reversal is blocked by H89, an inhibitor of PKA. These observations suggest that Alphabeta acts directly on the pathways involved in the formation of late LTP and agents that enhance the cAMP/PKA/CREB-signaling pathway have potential for the treatment of AD.

Integrity signals

Registry

Crossref · 10.1073/pnas.172504199

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vitolo, O. V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O., & Shelanski, M.
Affiliations
  • New York University (US)
  • Taub Institute for Research on Alzheimer's Disease and the Aging Brain and Department of Genetics and Development, Columbia University, New York, NY 10032; and Nathan Kline Research Institute, New York University School of Medicine, New York, NY 10016
Venue
Proceedings of the National Academy of Sciences
Published
2002-09-20
Volume
99
Issue
20
Pages
13217-13221
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1970164987
Cited by
534
References
27
Citations by year
2026: 19 · 2025: 18 · 2024: 14 · 2023: 22 · 2022: 17 · 2021: 23 · 2020: 22 · 2019: 29 · 2018: 17 · 2017: 30 · 2016: 17 · 2015: 35 · 2014: 29 · 2013: 29 · 2012: 22
FWCI
8.59
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
Keywords
amyloid-beta, Alzheimer's disease, protein kinase A, CREB phosphorylation, long-term potentiation, cAMP signaling, rolipram, forskolin, H89, PKA regulatory subunit, hippocampal neurons, spatial memory
MeSH terms
Cyclic AMP, Animals, Cells, Cultured, Electrophysiology, Hippocampus, Models, Biological, Neurons, Phosphorylation, Time Factors, Blotting, Western, Signal Transduction, Amyloid beta-Peptides, Rats, Sprague-Dawley, Cyclic AMP Response Element-Binding Protein, Long-Term Potentiation, Cyclic AMP-Dependent Protein Kinases, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review